Biotechnology News and Research

RSS

Bayer Crop Science uses Chromatin's proprietary mini-chromosome technology

Chromatin Inc. and Bayer CropScience announced today that they have entered into a technological alliance and license agreement to use Chromatin’s proprietary mini-chromosome technology for crop improvement.

20 Aug 2009

SCS becomes the first IT systems integration services provider to join Medidata’s ASPire to Win program

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that Sumisho Computer Systems Corporation (SCS) has become the first IT systems integration services provider to join Medidata’s ASPire to Win® program for contract research organizations (CROs) and service providers.

20 Aug 2009

Advaxis awarded $210,000 for development of a dual antigen vaccine

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.

20 Aug 2009

Helicos Genetic Analysis System to aid Ontario Institute for Cancer Research scientists in the study of cancer genomics

Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.

20 Aug 2009

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

MedImmune, Women's Professional Soccer (WPS) and the American Youth Soccer Organization (AYSO) today officially launched "Don't Play with the Flu,"((TM)) a national health awareness campaign that aims to highlight the importance of getting a seasonal influenza vaccination every year.

20 Aug 2009

Universal Detection Technology signs new distribution agreement for bioterrorism technologies

Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that has signed a distribution agreement with Strategic Response Initiatives, a New York based defense firm specializing in all phases of emergency preparedness planning for a wide range of defense, public and private sector organizations.

20 Aug 2009

Official launch of the FocusUP website announced

HST Global, Inc. today announced the official launch of the FocusUP® Website located at www.focusup.com FocusUP is the cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.).

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Catalent Pharma Solutions completes the first FDA general cGMP audit

Catalent Pharma Solutions announces the recent successful completion of the first FDA general cGMP audit and pre-approval inspection of its Buenos Aires, Argentina pharmaceutical softgel facility, with no reported observations on FDA Form 483.

20 Aug 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.

20 Aug 2009

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

19 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

AstraZeneca Canada files a New Drug Submission (NDS) for FluMist in Canada

AstraZeneca Canada Inc. announced today that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada.

19 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

Novavax reports positive preclinical results for H1N1 influenza VLP vaccine

Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA) for the production of generic Omeprazole Sodium injections.

19 Aug 2009

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

GENova Biotherapeutics, Inc., ("GENova") - (OTCBB: GVBP.OB), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

19 Aug 2009

Amarex joins OmniComm Systems' CRO Preferred Program

OmniComm Systems, Inc., a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III trial investigating the use of a medical device for wound healing.

19 Aug 2009

Biotechnology News and Research

Bayer Crop Science uses Chromatin's proprietary mini-chromosome technology

SCS becomes the first IT systems integration services provider to join Medidata’s ASPire to Win program

Advaxis awarded $210,000 for development of a dual antigen vaccine

Helicos Genetic Analysis System to aid Ontario Institute for Cancer Research scientists in the study of cancer genomics

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

Universal Detection Technology signs new distribution agreement for bioterrorism technologies

Official launch of the FocusUP website announced

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Catalent Pharma Solutions completes the first FDA general cGMP audit

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

The Gambia introduces pneumococcal immunisation programme

AstraZeneca Canada files a New Drug Submission (NDS) for FluMist in Canada

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

Novavax reports positive preclinical results for H1N1 influenza VLP vaccine

Bioheart's executive management team strengthened by the inclusion of board members

New production technology to develop vaccine for norovirus

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

Amarex joins OmniComm Systems' CRO Preferred Program

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News